Viking stock price range at end of first trading week | Categorical | | | 8 months ago | |
Viking market cap above $10 billion by end of 2024? | Binary | | | 8 months ago | |
Change in Viking shareholder count six months post-IPO | Categorical | | | 8 months ago | |
Viking IPO first-day close above $24? | Binary | | | 8 months ago | |
Viking's first quarterly revenue post-IPO | Categorical | | | 8 months ago | |
Will Viking Therapeutics' stock price double by mid-2025? | Binary | | | 2 months ago | |
Viking announces dividend within six months post-IPO? | Binary | | | 8 months ago | |
FDA approval status of VK2735 for obesity by end of 2025? | Categorical | | | 2 months ago | |
Viking Therapeutics initiates Phase 2 study of oral VK2735 by end of 2024? | Binary | | | 2 months ago | |
Viking Therapeutics stock price rises another 20% by end of 2024? | Binary | | | 2 months ago | |
Outcome of Phase 2 study of oral VK2735 by mid-2025? | Categorical | | | 2 months ago | |
Viking discusses VK2735 injectable with FDA by end of Q4 2024? | Binary | | | 2 months ago | |
VK2735 market share vs competitors by end of 2025? | Categorical | | | 2 months ago | |
Will Viking start Phase 2 trials for VK2735 by end of 2024? | Binary | | | 2 months ago | |
Outcome of next major VK2735 trial by mid-2025? | Categorical | | | 2 months ago | |
Who will lead the obesity treatment market by end of 2025? | Categorical | | | 2 months ago | |
VK2735 market share in obesity drugs by end of 2025? | Categorical | | | 2 months ago | |
Will VK2735 receive FDA approval by end of 2025? | Binary | | | 2 months ago | |